Systemic Sclerosis Insights (9.13.2024)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Read Article
Pooled data from BE MOBILE 1 & 2 RCTs shows Bimekizumab (dual-IL-17A/F inhib) may protect against uveitis in axSpA pts. N=349 pts - 0.6% BKZ vs 4.6% placebo developed uveitis (1.8 vs 15.4/100 PYs); even in pts w/ Hx of uveitis (6.2 vs 70/100 PYs; p=0.004) https://t.co/f8Uk0rEg86 https://t.co/mY1ikcGCNP
Dr. John Cush @RheumNow( View Tweet )
Running with Data (8.30.2024)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com - including tips on steroids, MAS, and myositis testing.
Read Article
Early axSpA defined by ASAS -- duration of symptoms ≤2 years; axial symptoms defined as cervical/thoracic/back/buttock pain or morning stiffness; regardless of Xray damage. ASAS community endorsed this proposal (88% in favour). https://t.co/JEviEgyIql https://t.co/jw11UsL6Iv
Dr. John Cush @RheumNow( View Tweet )
Antibiotics May Increase Inflammatory Arthritis Risk
A Danish registry study has shown that amongst those patients who develop inflammatory arthritis (IA), antibiotics use was more frequent when compared to the background population (BP).
This isn't the first time this association between antibiotic usage and futher
Among spondyloarthritis patients with clinical enthesitis, 68% had no ‘active enthesitis’ on ultrasound. Conversely, of those without signs of clinical enthesitis, 15% showed subclinical enthesitis on ultrasound
↓ https://t.co/aVEvOmcEHK
ACR_Journals @ACR_Journals( View Tweet )
ASLeap: Higher Dose Secukinumab in Ankylosing Spondylitis
Ankylosing spondylitis (AS) patients not responding to usual dosing with secukinumab (150 mg) after 16 weeks were dose escalated to SEC 300 mg, but failed to show improvement by week 52.
https://t.co/EJvoBlW9or https://t.co/tYb1fIA3pw
Dr. John Cush @RheumNow( View Tweet )
Higher Cancer Rates (8.16.2024)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com, noting his concerns about diet, cancer, ILD, death and dosing challenges.
Read Article
Rheums! Have a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/GV6WjsqZBH https://t.co/9l9qyJpg3I
Dr. John Cush @RheumNow( View Tweet )
ASLeap: Higher Dose Secukinumab in Ankylosing Spondylitis
Ankylosing spondylitis (AS) patients not responding to usual dosing with secukinumab (150 mg) after 16 weeks were dose escalated to secukinumab (SEC) 300 mg, but failed to show improvement by week 52.
Read Article
Less Mortality with GLP-1 Agonists in Rheumatic Patients
A recent article in PLOS ONE has shown that treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists (GLP-1-RAs) was associated with a significant lowering of risk of all-cause mortality and major adverse cardiovascular events in patients with immune-mediated inflammatory
Read Article
Depends on Where You’re Looking (8.9.2024)
https://t.co/GDAN37DJSx https://t.co/jVoumC00r5
Dr. John Cush @RheumNow( View Tweet )
Full Read Overview of the safety of bDMARDs/tsDMARDS - contraindications, precautions, & boxed warnings for treatment of RA, PsA, SpA, JIA - safety checklist for a class of drugs you use and diseases you treat https://t.co/5chrS3sW8i https://t.co/twSv4Zs9r3
Links:
Dr. John Cush @RheumNow( View Tweet )
Finding Spondylitis Among Psoriasis, Uveitis and Colitis Patients
Maksymowych and colleagues have shown that screening patients with either psoriasis, iritis, or colitis may yield a surprising percentage meeting ASAS criterial for axSpA.
https://t.co/lVCdGnMVaT https://t.co/jFILeHrQXj
Dr. John Cush @RheumNow( View Tweet )
Depends on Where You’re Looking (8.9.2024)
Dr. Jack Cush reviews the news and journal reports from RheumNow.com this week.
Read Article
Finding Spondylitis Among Psoriasis, Uveitis and Colitis Patients
Maksymowych and colleagues have shown that screening patients with either psoriasis, iritis, or colitis may yield a surprising percentage meeting ASAS criterial for axial spondyloarthritis (axSpA).
Read Article
Pt Reported Outcomes in axSpA or PsA may be interpreted differently if fibromyalgia is present. ASDAS-CRP, & duration of lumbar AM stiffness were not affected by FM, yet FM significantly caused higher scores in axSpA or PsA all assessments https://t.co/v8wFzIVxUr https://t.co/eIXRoktYja
Dr. John Cush @RheumNow( View Tweet )
Full Read Overview of the safety of bDMARDs/tsDMARDS - contraindications, precautions, & boxed warnings for treatment of RA, PsA, SpA, JIA - safety checklist for a class of drugs you use and diseases you treat https://t.co/TIdCtJjF21 https://t.co/UE0nGbESDB
Links:
Dr. John Cush @RheumNow( View Tweet )
Study of 136 referred LBP pts (71 w/ DDD, 38 DISH, 27 axSpA) found significant overlap of imaging features in all 3. SpA-like spine CR features were found in 1/4 of patients with DISH, and MRI BM edema found in 1/3 of those patients. https://t.co/dKIcuE3IGZ https://t.co/OITtOKEuNC
Dr. John Cush @RheumNow( View Tweet )
New Classification Criteria for Juvenile Axial Spondyloarthritis
An expert panel has published new and validated classification criteria for axial disease in children with juvenile spondyloarthritis (SpA; AxJSpA).
https://t.co/kxtHlEk5XG https://t.co/jKAp9W5Di1
Dr. John Cush @RheumNow( View Tweet )
New Classification Criteria for Juvenile Axial Spondyloarthritis
An expert panel has published new and validated classification criteria for axial disease in children with juvenile spondyloarthritis (SpA; AxJSpA).
The authors used a systematic literature review to evaluate the
Potential of Radiomics to Predict TNF Therapy Outcomes in axSpA
Dr. Bella Mehta interviews Dr. Vincenzo Venerito about abstract POS0236 at Eular 2024 in Vienna, Austria.
https://t.co/ZR5pFINagR https://t.co/bEWjSXWlB0
Dr. John Cush @RheumNow( View Tweet )
UK study of pneumococcal vaccination in UK, shows IMID pts had suboptimal vax against pneumococcus. In 32 277 pts (RA 14151, IBD 13631, SpA 3804, SLE 691) saw 57% vaccinated; lower if <45 yrs (32%), IBD (42%). Vax not associated w/ IMID flare https://t.co/y5JHYaEpA9 https://t.co/zUXfDoqyal
Dr. John Cush @RheumNow( View Tweet )
Pollution and Autoimmunity (7.12.2024)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
Bimekizumab (dual-IL-17A/F inhib), may prevent uveitis in patients with axSpA. In phase 3 RCTs (MOBILE 1 & 2) double-blind period, uveitis seen in 0.6% on BKZ vs 4.6% on PBO (p=0.001). In pts w/ hx uveitis, again lower w/ BKZ (6.2/100 PYs vs 70.4/100 PYs) https://t.co/v0wMK45chz https://t.co/CVPdg1k41V
Dr. John Cush @RheumNow( View Tweet )
Recent Blogs
With their publication in June 2022 (1), the 3rd iteration of the Group for Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Treatment recommendations for Psoriatic Arthritis (PsA) may have set a record or sorts.
Read Post
